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ABSTRACT
With the advent of transcatheter mitral valve replacement (TMVR), the concept of the neo–left ventricular outflow tract
(LVOT) was introduced and remains an essential component of treatment planning. This paper describes the LVOT
anatomy and provides a step-by-step computed tomography methodology to segment and measure the neo-LVOT while
discussing the current evidence and outstanding challenges. It also discusses the technical and hemodynamic factors that
play a major role in assessing the neo-LVOT. A summary of expert-based recommendations about the overall risk of LVOT
obstruction in different scenarios is presented along with the currently available methods to reduce the risk of LVOT
obstruction and other post-procedural complications. (J Am Coll Cardiol Img 2020;-:-–-) © 2020 by the American
College of Cardiology Foundation.
M itral regurgitation is highly prevalent, re-ported in almost 10% of patients >75years of age (1), with at least one-half of
these patients are not suitable for surgical interven-
tion given comorbidities. Left untreated, 90% of
these will experience at least 1 heart failure hospital-
ization, with a mortality rate of 50% within 5 years
(2,3). Thus, transcatheter mitral valve replacement
(TMVR) has gained much interest as a new, less inva-
sive treatment option for patients with significant
mitral regurgitation and high surgical risk (4–6).
In addition to numerous clinical trials and devices
specifically designed for the native mitral space (4–6),
TMVR also includes previously approved trans-
catheter aortic valve replacement (TAVR) valves for
use in the mitral space, principally for use in valve-in-
valve (ViV), valve-in-ring (ViR), or valve-in-mitral
annulus calcification (ViMAC).
The structure and function of the mitral valve is
complex, comprising a nonplanar, noncircular
annulus, variable leaflet lengths and heights, and
heterogeneous anatomy of the subvalvular appa-
ratus. These lie in close proximity to adjacent
anatomic structures such as the left circumflex artery
and the left ventricular outflow tract (LVOT). Funda-
mental to TMVR procedural success is a valve
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prosthesis that allows for adequate anchoring
and sealing, while being able to accommo-
date the dynamic deformation of the mitral
annulus during the cardiac cycle (7,8). Such a
device, however, carries a risk of narrowing
the LVOT and displacing the native anterior
mitral valve leaflet (AML), resulting in LVOT
obstruction (LVOTO) (9,10). Historically,
LVOTO has been considered a rare but
recognized complication following surgical
mitral valve interventions in cases in which
the AML is preserved, or in which the surgical
valve was positioned with the stent post
angulated toward the LVOT. TMVR-related
LVOTO, however, is feared and is poten-
tially fatal, and is reported in approximately
7% to 9% of TMVR procedures (7). For these
reasons, and building on experience with
transcatheter aortic valve implantation,
contrast-enhanced multiphasic computed
tomography angiography (CTA) has quickly
become embedded as an essential comple-
mentary tool in treatment planning, device
selection, and patient-specific procedural risk strati-
fication prior to TMVR (8,9). Given that threatened
LVOTO is an exclusion criteria for approximately 50%
of patients in contemporary clinical trials (10), our
capability for accurate modelling of the post-
procedure neo-LVOT with CTA is crucial for proce-
dural success. This document aims to provide prac-
tical recommendations for current protocols and
techniques used in the assessment of risk of LVOTO
post-TMVR (Central Illustration).
THE CONCEPT OF THE NEO-LVOT
ANATOMY OF THE NATIVE LVOT AND THE NEO-LVOT.
The native LVOT is the anatomic tract confined by the
region of potential interaction between a proposed
implanted device and the opposing basal to mid
anteroseptal wall of the LV (Figure 1). TMVR devices
comprise fabric-covered stent struts that protrude
into the basal LV cavity. After implantation, the
TMVR pins the native AML open, displacing it toward
the septum, thereby creating a “neo-LVOT,” confined
by the displaced AML, the stent of the TMVR, and the
basal-mid anteroseptal LV wall (11), similar in concept
to “fixed” systolic anterior motion of the mitral valve.
Implantation of an artificial valve into a native
mitral annulus landing zone decreases the available
surface area for blood to flow into the patient’s native
LVOT. In the transcatheter world, implantation of a
closed-cell TMVR device necessitates an in-depth
understanding of the entire threatened LVOT,
because of the potential of fixed obstruction post–
device implantation. Contrary to open-cell technol-
ogy, in which leaflets open and close, allowing blood
flow into the LVOT during systole, closed-cell TMVR
devices created a fixed LVOTO, with the depth of
protrusion of the prosthetic valve into the LVOT be-
ing the main predictor of obstruction (12). The risk of
LVOTO post-TMVR is greater in the presence of an
elongated native AML, which can produce dynamic
LVOTO due to systolic anterior motion of the AML
(Figure 2).
Acute LVOTO can be a catastrophic complication
occurring immediately following TMVR, causing he-
modynamic collapse and potential periprocedural
death (10). More chronic LVOTO may also be seen as a
consequence of LV reverse remodeling after mitral
regurgitation correction, and patients are typically
preload dependent and sensitive to volume changes.
Chronic LVOTO increases LV afterload and may
introduce adverse hypertrophic LV remodeling, pre-
disposing to subsequent ventricular failure, particu-
larly in the context of underlying LV dysfunction (13).
SEGMENTATION AND MEASUREMENT OF THE
NEO-LVOT. Given the dynamicity and complex
interplay of the mitral prosthesis, LVOT, and LV in
the generation of neo-LVOTO, contrast-enhanced
CTA data acquisition should cover the entire systolic
cardiac cycle, either by means of retrospectively
electrocardiography-gated data acquisition, or by
prospective electrocardiography-triggered data
acquisition with “whole-heart” detector coverage.
Datasets should be reconstructed at minimum of 10%
R-R interval (preferably at 5% of R-R intervals [i.e., 20
phases]), and optimally without dose modulation.
Presence of atrial fibrillation or faster heart rates can
compromise data quality, and absolute millisecond
reconstruction at 50-ms intervals can improve image
quality when compared with % of R-R intervals.
A 3-step method for neo-LVOT measurement in
native mitral valve disease is described in detail in
Figure 3. Methods of segmentation of the native
D-shaped mitral valve annulus using CTA have been
comprehensively described previously. In brief, the
D-shaped annulus is formed by truncating the
anterior horn from the saddle-shaped annulus at
the level of the fibrous trigones, facilitating and
standardizing the sizing for TMVR. Typically, pre-
TMVR, 3-dimensional segmentation of the mitral
annulus is performed in end-diastole by measuring
the intersection of the left atrium and LV blood flow,
commonly identified by the basal insertion points of
the anterior and posterior mitral leaflets. Post-
processing provides the annular area and perimeter,
ABBR EV I A T I ON S
AND ACRONYMS
AML = anterior mitral valve
leaflet
CTA = computed tomography
angiography
LV = left ventricle/ventricular
LVOT = left ventricular outflow
tract
LVOTO = left ventricular
outflow tract obstruction
MAC = mitral annular
calcification
MVARC = Mitral Valve
Academic Research Consortium
TAVR = transcatheter aortic
valve replacement
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and major and minor dimensions. This step can be
done with standard post-processing CTA software (8).
This same segmentation is repeated in mid- or end-
systole, which serves as the anatomic landmark for
CTA-based virtual simulation of device implantation,
by embedding either a device-specific contour (using
a stereolithographic file) or a generic cylindrical or D-
shaped contour. The minimal cross-sectional area of
the neo-LVOT at the site of the greatest encroachment
and narrowing can be planimetered using a multi-
planar reformat plane orthogonal to a centerline
plotted through the LVOT. This step requires a dedi-
cated TMVR modulus, which allows the simulation of
the residual neo-LVOT, while accounting for the
prosthesis characteristics.
HEMODYNAMIC DEFINITION OF LVOTO POST-TMVR.
The upper bound for acceptable LVOT gradients post-
TMVR has not yet been defined. According to the
Mitral Valve Academic Research Consortium
(MVARC) criteria, surgical device–related, iatrogenic
LVOTO is defined as an increment in peak LVOT
gradient of >10 mm Hg from baseline, derived from
echocardiography (14). Varying thresholds of peak
LVOT gradient post-TMVR have been proposed. In
clinical trials evaluating novel investigational TMVR
devices not yet approved for commercial implanta-
tion, the general accepted definition for early signs of
LVOTO and gradient adhere to MVARC recommen-
dations of 10 mm Hg. In patient populations at risk of
critical LVOTO who are ineligible for investigational
CENTRAL ILLUSTRATION Key Elements of Computed Tomography Acquisition and Evaluation
for Neo-LVOT Obstruction Risk During Transcatheter Mitral Valve Replacement
Anatomic definition of Neo-LVOT Hemodynamic Definition
of LVOT Obstruction



















• Asymmetrical septal hypertrophy
• Perpendicular aorto-mitral angulation
• Elongated anterior leaflet
• Device related
• Full Cardiac Cycle
• Data Set Reconstruction of 5-10%
   Interval
• Mid to End Systole Phase
  Reconstruction
• LVOT peak gradient >10 mm Hg from
  baseline echocardiography
• Peak gradient >30 mm Hg. Haemodynamically
  significant >50 mm Hg
• LVOT Area <1.7-1.9 cm2
Reid, A. et al. J Am Coll Cardiol Img. 2020;-(-):-–-.
Approach to computed tomography imaging and analysis for left ventricular outflow tract (LVOT) obstruction during transcatheter mitral
valve replacement.
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TMVR devices due to complex anatomy (i.e., off-label
use of commercially available devices such as the
Edwards SAPIEN transcatheter heart valve [Edwards
Lifesciences, Irvine, California]) LVOTO has been
proposed as a peak gradient of >30 mm Hg, with he-
modynamically significant LVOTO as a peak gradient
of >50 mm Hg (15). To date, there is no consensus.
Early technologies have demonstrated the presence
of potential positive and negative LVOT remodeling
post–TMVR device implantation. Our understanding
of clinically relevant obstruction being >30 mm Hg
has been inferred from data defined in the setting of
hypertrophic obstructive cardiomyopathy, and the
ability to apply this in a dynamically remodeling LV in
the TMVR population is not yet well studied (16).
There is an inverse correlation between LVOT
gradient and neo-LVOT area post-TMVR (17). Inter-
estingly, computational models using CT datasets,
facilitating simulation of different virtual valves and
LVOT flows, confirm the relationship between LVOT
area and pressure gradient in TMVR. A reduction of
35% in LVOT area has been shown to generate expo-
nential increases in LVOT pressure gradients and
reduced LV emptying, inducing low cardiac output
(18). The finding of a nonlinear relationship between
neo-LVOT area and pressure gradient has been sup-
ported by other computational models. Alharbi et al.
(19) recently confirmed that the neo-LVOT area is the
most important factor to influence the pressure
gradient. Pre-procedural estimation of the neo-LVOT
area is therefore a fundamental aspect of the
patient-specific risk stratification, but uncertainties
still exist. The lack of early prospective and TMVR-
specific data generated a reliance on extrapolated
hypertrophic obstructive cardiomyopathy data to
derive conservative consensus threshold of a minimal
neo-LVOT cross-sectional area of 2 cm2 in mid-systole
(20), which has been used in several clinical trials but
has resulted in high rates of screening failure and
ineligibility for TMVR (10).
The current TMVR literature comprises small,
heterogeneous studies, including a mixed population
of patients undergoing TMVR for native valve dis-
ease, failed surgical replacements or repair, and
calcific mitral valve disease. Nevertheless, these data
have allowed for the validation of the technique by
demonstrating excellent correlation between
predicted and with actual neo-LVOT area on post-
procedural CTA (17). Furthermore, small pre-
procedural simulated neo-LVOT area has been
shown correlate with post-procedural adverse clinical
outcomes (17). Despite this, the threshold for the
smallest neo-LVOT area that will generate acceptable
post-implantation outcomes and gradients has been
challenging to establish and likely not as dichoto-
mous and binary as proposed. Thresholds of
neo-LVOT area of 1.7 to 1.9 cm2 have been demon-
strated to predict LVOTO according to MVARC
criteria, with high sensitivities and specificities, but it
is important to note that these studies used different
TMVR technologies (17,21). Current neo-LVOT cutoffs
of 1.7 to 1.9 cm2 have largely been studied on closed
cell-TMVR technologies such as the Edwards SAPIEN
3 and Tendyne (Tendyne, Roseville, Minnesota)
valves. This neo-LVOT cut-off is not yet well under-
stood for hybrid cell technologies including the Evo-
que and Medtronic Apollo device (Edwards
Lifesciences) where there is an open frame docking
system external to an internal closed valve design.
Furthermore, mid-systolic neo-LVOT area is not the
sole determinant of LVOTO, and more thoughtful
integration of ventricular and device geometry, as
well as LV function and AML, are required.
KEY CONSIDERATIONS IN THE ASSESSMENT
OF THE NEO-LVOT AREA
PHASE SELECTION. Both the native mitral valve
complex (leaflet, annulus, and subvalvular apparatus)
and neo-LVOT are dynamic structures, changing size
and shape throughout the cardiac cycle. Echocardio-
graphic and CTA-derived data identify the LVOT area
FIGURE 1 Chamber Reconstruction of a Cardiac Computed Tomography









The left ventricular outflow tract (LVOT) is defined by the basal-mid
anteroseptal wall and the mitral intervalvular fibrosa (orange dotted line).
Following valve placement, the prosthetic valve is protruding into the basal
left ventricular cavity (green dotted line) to produce the neo-LVOT
(red dotted line).
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as being smallest at end-systole. However, there is
confusion in terminology between echocardiographic
and CTA datasets. Owing to the inherent delay
between electrocardiography sensing and echocar-
diographic contract, the end-systole on a parasternal
long-axis view of the LV most commonly correlates to
55%, or early diastole on CTA. CTA does not suffer
from electrocardiography sensing delays long docu-
mented in echocardiography, although the timing of
phase reconstruction does vary across vendors,
meaning 50% of the R-R interval is not the same thing
across CT scan platforms. Safe TMVR planning must
include an understanding of the dynamism of the
structures within the LVOT during systole. LV cavity
size as a sole indicator of phase selection is addi-
tionally not an adequate predictor of neo-LVOT risk,
as early diastole is commonly when LV volume is
smaller on CTA and echocardiography. Safety checks
must be employed to ensure that in systolic phases
the aortic valve is open, and not closed, as physio-
logically, in a nondiseased aortic valve, systole is
defined as the phase when the valve is open.
In the Intrepid Global Pilot Study cohort, Meduri
et al. (22) identified that pre-procedural end-systolic
prediction of neo-LVOT area was found to be smaller
than the true post-procedure neo-LVOT area
(in ascending size) at end-systole, multiphasic, and
early systole. This study emphasized the importance of
understanding TMVR device technology and potential
presence or absence of device conformational changes
with relation to the patient’s native mitral annulus. In
the presence or absence of TMVR device deformation,
there would be potentially associated neo-LVOT
prediction modeling changes that would need to be
accounted for. Additionally, multiphasic and early
systolic neo-LVOT allowed better discrimination of
post-procedure LVOT gradient and better prediction of
the post-procedure neo-LVOT, with the added poten-
tial for increasing eligibility for TMVR (22). It is
essential to recognize that the majority of patient
screening to date has relied on adjudication of the
neo-LVOT in mid- and end-systole, and while
hypothesis generating, the recent work with the
Intrepid device may be device specific, and there is not




An example of dynamic left ventricular outflow tract (LVOT) obstruction. Following transcatheter mitral valve replacement, there is systolic
anterior motion of the residual native anterior mitral leaflet (arrow) as demonstrated in (A) computed tomography and (B, C) 2-dimensional
echocardiography. (D) The resulted dynamic LVOT obstruction is seen with the LVOT continuous-wave Doppler.
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enough evidence to transition to early systolic mea-
surements for risk prediction. This work does also
emphasize the need to improve our pre-procedural
measurements by learning from post-TMVR CTA
datasets, which are invaluable to refine our under-
standing of device-specific post-implant remodeling
and its impact on the neo-LVOT geometry.
ANATOMICAL HIGH-RISK FEATURES. LVOT area is
affected by LV size, thickness, right ventricular size,
function, dynamism, and loading conditions. Previ-
ous studies of patients following surgical mitral valve
replacement have shown that LVOT area and the risk
of LVOTO is increased in patients with small, hyper-
contractile LV as well as with the presence of septal
hypertrophy or an asymmetrical septal bulge
(>15 mm) (16,18,20,23,24). Similar physiology is
anticipated in TMVR. It is, of course, impossible to
completely predict and incorporate a patient’s phys-
iologic response to a TMVR insertion, changes in their
cardiac output once the degree of mitral regurgitation
is reduced, and the degree of the post-procedural LV
remodeling and changes in dynamism into the pre-
procedural risk assessment of LVOTO. However,
conceptually, small end-systolic LV dimensions are
likely to predict neo-LVOTO and thus obviate the
need for time-consuming image post-processing (25).
Mitral valve and chordal anatomy vary between
patients but is an important consideration in the
prediction of LVOTO. An elongated AML with
redundant chordae is an accepted risk factor for
dynamic LVOTO, although there are no currently
accepted thresholds (26). The current available TMVR
simulation software do not account for the residual
AML, which can protrude toward the neo-LVOT,
causing dynamic LVOTO. Bulky calcification in the
AML has the potential to displace the LVOT following
valve placement (27). Native mitral annular dynam-
icity influences LVOT area throughout the cardiac
cycle; however, this is lost following prosthetic valve
implantation. Thus, the current method of neo-LVOT
area analysis still has room for improvements.
Aortomitral angulation describes the angle be-
tween the annular planes of the aortic and mitral
valve and is typically measured in end-systole.
Conceptually, a mitral annular trajectory (and there-
fore TMVR trajectory) running parallel to the LVOT
FIGURE 3 Stepwise Approach to Neo-LVOT Segmentation in Native Mitral Regurgitation With CT
Step & Description
Step 1: Multipoint segmentation of the D-shaped
native mitral valve annulus, as previously described
(15). Annulus size (area, septolateral [SL], and 
intercommissural [IC] distance) is used to determine
eligibility for, and sizing of the transcatheter mitral
valve replacement.
Step 2: Virtual implantation of TMVR (here a 
Tendyne device is modelled, and shown in
3-chamber, short axis, and 4-chamber). The device 
size can be manually adjusted.
Step 3: Segmentation of the neoLVOT using a
centreline technique. The center line is manuaIly
drawn, following the trajectory of the LVOT (orange
Iine). The neo-LVOT is visually interrogated using the
green slider. The smalIest neo-LVOT area (curved 
orange dotted line) can then be measured (6.5 cm2 
in this case).
IC ¼ intercommisure; LVOT ¼ left ventricular outflow tract; SL ¼ septolateral; TMVR ¼ transcatheter mitral valve replacement.
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long axis would result in minimal risk of LVOTO,
whereas a perpendicular orientation, and subsequent
canting of the TMVR trajectory toward the septum,
would result in maximal risk. It is recommended that
aortomitral angulation is considered together with
LVOT, septal, and LV geometry, rather than as a sin-
gle, stand-alone factor. The importance of the aorto-
mitral angle more commonly affects valve depth
deployment, valve coaxiality, and feasibility of
different transcatheter or surgical approaches to
maximize LVOT area post-TMVR. Furthermore,
quantification may be limited by subjective assess-
ment of the LVOT long axis, although facilitated
workflows may improve this observer variability (8).
DEVICE FEATURES. The varying features of individ-
ual TMVR prosthesis plays a key role in estimation of
the neo-LVOT. The currently available devices have
different structures, which is outside the scope of this
paper, but in general, the greater the depth of device
protrusion into the LV and extent of device flaring at
LVOT level will lead to narrower and smaller
neo-LVOT area (11,12). Moreover, it is currently
impossible to predict the end position and shape of
the implant, and the degree of compression the
device will undergo, particularly in nitinol-based
devices. For this reason, in borderline cases, the
true neo-LVOT area may be larger (if greater
compression occurs) or smaller (if there is significant
LV protrusion) than that predicted.
LVOT OBSTRUCTION RISK IN SPECIFIC
PATIENT POPULATIONS
MITRAL ViV AND ViR. In the context of a failing
bioprosthesis, mitral ViV implantation is typically
performed with a transcatheter aortic valve into the
mitral position. The risk of neo-LVOTO in this group
is higher than that compared with native TMVR,
occurring in 2.2% to 2.6% of cases (17,28). The new
prosthesis pins the failing valve leaflets open, envel-
oping the open valve stent cells of the TMVR, and
creating a covered cylinder which may induce a fixed
obstruction (12,28). Risk of neo-LVOTO may vary
depending on the intrinsic features of the original
implant. Because the failing leaflets will only extend
at most to the tip of the original stent posts, the
height, rather than size, of the failing prosthesis is an
important factor in determining the risk of neo-LVOT
anatomy and obstruction. Canting of the surgical
valve toward the septum, as opposed to parallel, may
also predispose to neo-LVOTO (12,29). Orientation of
the stent struts within the native mitral valve annulus
may not influence the neo-LVOT area but may influ-
ence the ability to achieve adequate skirt–neo-LVOT
area in high-risk patient populations requiring the
LAMPOON procedure. Bench testing indicates a ten-
dency of porcine valve leaflets to crumple, compared
with pericardial valve leaflets, which remain rigid and
upright. Pericardial valve leaflets are also longer, and
therefore likely to cover more surface area of the
TMVR stent. These are, then, conceptually more
likely to form a covered cylindrical stent and
neo-LVOTO (12). A method for neo-LVOT area using
double oblique, multiplanar reformation is described
in Figure 4. Alternatively, dedicated software with
virtual valve implantation may be performed
(Figure 5). Measurements of the surgical prosthesis
should be performed to confirm the surgical report
and be done along the inner border, taking care to
optimize image acquisition (using body size appro-
priate tube voltage and tube current), image recon-
struction (using thin slices and without cardiac
motion), and wide grayscale display settings to
minimize beam hardening and blooming artifacts.
Similar to ViV, mitral ViR is performed using a
transcatheter aortic valve (Figure 6); however, ViR is
associated with relatively higher rates of LVOTO,
occurring in 5% to 8% of procedures (28,30,31).
Longer AML length appears to be a particularly rele-
vant anatomic risk factor for LVOTO; further study
and integration of other anatomic and procedural risk
factors are likely to be required to define specific
thresholds.
Conceivably, the type of previous annuloplasty
ring affects the degree of risk of LVOTO in ViR cases
(28). Rigid rings do not allow for full expansion of the
percutaneous valve; instead, the valve deforms to fit
the oval shape of the ring, risking valve malfunction.
By contrast, flexible and semi-rigid rings will conform
to match the circular shape of the percutaneous
valve. While preferred for valve function, ViR dis-
places the AML toward the LVOT and septum, thereby
increasing the risk of LVOTO (32,33). Recent data,
however, identified no difference in outcomes
amongst the varying ring types, but in small numbers
(31). Last, it bears repeating that current TMVR
simulation software for the ViR TMVR procedure do
not account for the residual AML, which can protrude
toward the neo-LVOT, causing dynamic LVOTO.
Common to both procedures is the interplay be-
tween the sewing ring annular plane and LV. Recent
published data suggest that in addition to an antici-
pated neo-LVOT area of <1.9 cm2, an annulus-to-
septal distance of <17.8 mm, an LV end-diastolic
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FIGURE 4 Stepwise Approach to Neo-LVOT Segmentation in the Setting of a Bioprosthetic Mitral Valve
Step 1: Starting with multi-planar images in the
default axial (red box), sagittal (green box) and
coronal (blue box) orientation, center the cross-
hairs onto the center of the mitral valve.
Step 2: Rotate the cross-hairs in the axial and
sagittal views to intersect the LV apex and align
with the long axis of the left ventricle to depict
a double oblique short axis view of the sewing
ring of the surgical valve prosthesis.
Step 3: Rotate the crosshairs clockwise on the
short axis plane of the valve prosthesis to
intersect the aortic valve and run parallel to the
aortic root. This will generate a 3-chamber view
in the formally axial view (red box).
Step 4: Increase the maximal intensity
projection to visualise the three stent posts of
the valve prosthesis in the long axis views
(orange arrows).
Step 5: On the 3-chamber view, position and 
align the crosshairs on the intersection of the
level stent post tips and septal edge of the
prosthesis (yellow arrow). The dashed rectangle
represents the conceptual prosthesis 'space'.
Step 6: Rotate the crosshairs clockwise in the
3-chamber view to align with the LVOT 
trajectory.
Step 7: Reduce the maximal intensity projection
to visualize the LVOT in short axis (yellow arrow,
blue box).
Step 8: Zoom in to optimize the working view.
Step 9: The neoLVOT area can be planimetered.
The center of the crosshair represents the most
distal point of the septal aspect of the
prosthesis, which will form the inferior border
of the neo-LVOT (yellow dashed line).
LV ¼ left ventricle; LVOT ¼ left ventricular outflow tract.
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dimension of <48 mm, LV mass index >105 g/m2, and
relative wall thickness of >0.38 convey increased risk
of neo-LVOTO (17). Validation of these thresholds in a
larger cohort of patients is required.
Procedurally, transcatheter heart valves are gener-
ally oversized to reduce the risk of valve embolization
and paravalvular leak. The resultant flaring should be
taken into consideration during the pre-procedural
imaging assessment; however, this is challenging to
do quantitatively. Larger and longer transcatheter
heart valves, with deep implantation into the LVOT,
will likely decrease the neo-LVOT area (20). The field is
in need for TMVR-specific devices for ViV and ViR,
other than balloon-expandable TAVR devices.
VALVE-IN-MAC. LVOTO is the most important and
independent predictor of 30-day and 1-year mortality
(32) post-TMVR for TMVR ViMAC. Compared with ViV
and ViR, procedural mortality after LVOTO has been
reported to be as high as 45% in ViMAC (17).
The cause of LVOTO in this group ismultifactorial. It
has been described that intrinsically, severe posterior
MAC can push the mitral valve coaptation point atrial
and anteriorly, which along with AML then causes
LVOTO (34). Other studies have reported that systolic
anterior motion of the AML also causes LVOTO in these
patients (35). Furthermore, MAC is highly heteroge-
neous, and prediction the final positioning of the
TMVR device (in most cases, Edwards SAPIEN 3 TAVR
device has been used) is difficult to predict, and the
current method of prediction also does not account for
the dynamic interaction of the prosthesis and MAC, as
there is insufficient data to date with regard to the
FIGURE 5 Stepwise Approach to Neo-LVOT Segmentation in the Setting of a Mitral Bio-Prosthesis
Step & Description
Step 1: Segmentation of the prosthetic valve basal
ring. A 31mm Magna was segmented in mid-late
systole (40% in this case). The true internal
diameter (measured with the automatically
generated SL or Ie dimension) was 28.5 mm.
Step 2: Virtual implantation of a TMVR. A 29mm
Sapien S3 was modelled, and offset to the level of
the stent posts (yellow arrows).
Step 3: Segmentation of the neo-LVOT. The
center line is manually drawn as in native valves. The




LVOT ¼ left ventricular outflow tract; TMVR ¼ transcatheter mitral valve replacement.
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deformation of the MAC with radial stress (36). Pa-
tients with severe MAC are typically older, with
concomitant cardiac diseases such as aortic stenosis,
hypertension, and renal dysfunction, all of which
predispose the unfavorable anatomic and functional
characteristics such as small, hyperdynamic LVs with
LV hypertrophy (37,38).
FUTURE DIRECTIONS
To reduce the risk of LVOTO, various surgical and
transcatheter methods have been proposed. Given
that basal septal hypertrophy is an important
contributing risk factor in the development of
LVOTO, pre-procedural alcohol septal ablation has
also been proposed as a potential therapeutic strat-
egy, similar to its use in patients with obstructive
hypertrophic cardiomyopathy (39). The Achilles heel
of this technology is an increased incidence of
requirement for permanent pacemaker implantation
after alcohol septal ablation, the obligatory 2-week
wait time for the LV basal anteroseptum to remodel,
and the risk that patients may have appropriate target
vessels for Alcohol Septal Ablation. Historically, in
this patient population, the LAMPOON technology
was developed, with intention to lacerate the AML as
an adjunct to decrease the risk of LVOTO in this pa-
tient population By lacerating the native AML using









An 80-year-old patient presented with recurrent severe mitral regurgitation, 5 years after mitral valve repair with a 26-mm CE Physio mitral
annuloplasty ring. (A) Annuloplasty ring segmentation was consistent with the manufacturer’s sizing, the internal dimension was 24.6 mm,
and septolateral (SL) dimension was 17 mm. (B) A 3-dimensional rendering of the annuloplasty ring demonstrating segmentation of the inner
rim, which may be difficult to determine because of blooming artifact. Virtual implantation of a 23-mm circular valve with 15% atrial offset
was (C) applied and (D) a neo–left ventricular outflow tract (LVOT) area of 4.1 cm2 was measured, indicating low risk of neo-LVOT
obstruction. IC ¼ intercommissure; Pe ¼ perimeter.
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an electrified wire that traverses the leaflet, the cells
of the “unskirted” portion of the TAVR are exposed,
allowing blood to flow across, thereby increasing the
size of the neo-LVOT. The anticipated “skirt neo-
LVOT” can again be modelled pre-procedurally
(Figure 7) (26). The limitations of this procedure
include the understanding that it is technically chal-
lenging both from an interventional and imaging
intraprocedural skillset, and is not feasible in calcific
leaflets, and may not completely resolve neo-LVOTO
caused by the fabric skirt. Teams will need to
be ready for bail-out alcohol septal ablation if insuf-
ficient laceration of the AML occurs on the table.
Given these limitations, newer technology is being
evaluated looking at preemptive radiofrequency
septal ablation to decrease the risk of LVOTO post-
TMVR (40).
There is much to learn in the TMVR space. Three-
dimensional printing of anatomic models for neo-
LVOT evaluation have also been demonstrated, but
these are limited, of course, by their fixed anatomy,
high costs, and the lack of printing materials that
mimic human tissue (41). Patient-specific computer-
ized models of computational fluid dynamics are
under investigation (39), with the anticipation that
that they may overcome the limitation of a purely
geometric analysis. Using 3-dimensional finite
element models of the heart, both mechanical and
geometric properties of the valve and the heart can be
applied to predict LVOTO (39). Further study will be
required to determine the role of these approaches
across a wider spectrum of patients requiring TMVR.
Improved valve design includes lower profiles, in-
cludes anterior leaflet capture, and allows for more




The same patient from Figure 6 is presented to demonstrate the concept of the skirt neo-LVOT. (A) An Edwards SAPIEN 3 valve, with the
fabric skirt identified by the red arrows and blue dotted line. (B) This valve is then modeled as per Figure 6. The blue dotted line and red
arrows again represent the level of the skirt on the model. (C) If LAMPOON were performed, with laceration to the level of the skirt, the neo–
left ventricular outflow tract (LVOT) area at this level would be 5.0 cm2.
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atrial positioning. Such concepts are in their infancy,
and more data are required to determine their
efficacy.
CONCLUSIONS AND FUTURE DIRECTION
Patient-specific risk stratification prior to trans-
catheter therapy is the goal of procedural planning
with advanced imaging. CTA is integral to planning for
TMVR, with careful measurement of the neo-LVOT
area, which remains one of the most important pre-
dictors for iatrogenic LVOTO (Central Illustration).
Further refinement of the methodology through the
integration of post-TMVR CTA imaging in expanding
patient populations, with longer-term outcome
data, is essential to enhance patient selection and
simulation methodology, and to improve procedural
outcomes.
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